Katherine P. Ponder

4.4k total citations
83 papers, 3.4k citations indexed

About

Katherine P. Ponder is a scholar working on Genetics, Physiology and Molecular Biology. According to data from OpenAlex, Katherine P. Ponder has authored 83 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Genetics, 34 papers in Physiology and 32 papers in Molecular Biology. Recurrent topics in Katherine P. Ponder's work include Virus-based gene therapy research (39 papers), Lysosomal Storage Disorders Research (34 papers) and CRISPR and Genetic Engineering (15 papers). Katherine P. Ponder is often cited by papers focused on Virus-based gene therapy research (39 papers), Lysosomal Storage Disorders Research (34 papers) and CRISPR and Genetic Engineering (15 papers). Katherine P. Ponder collaborates with scholars based in United States, Brazil and Italy. Katherine P. Ponder's co-authors include Mark E. Haskins, Lingfei Xu, Cuihua Gao, M. Wayne Flye, Frances E. Leland, Gretchen Darlington, Milton J. Finegold, Savio L.C. Woo, Mark S. Sands and Shi-Rong Cai and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Investigation.

In The Last Decade

Katherine P. Ponder

83 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katherine P. Ponder United States 35 1.4k 1.4k 1.2k 718 514 83 3.4k
Akihiko Ito Japan 32 227 0.2× 1.5k 1.0× 387 0.3× 471 0.7× 340 0.7× 88 3.3k
Andrés F. Muro Italy 34 405 0.3× 2.1k 1.5× 382 0.3× 179 0.2× 336 0.7× 91 3.8k
Jean Michel Heard France 28 860 0.6× 1.1k 0.8× 588 0.5× 321 0.4× 116 0.2× 43 2.1k
Elizabeth L. Buza United States 27 905 0.6× 1.4k 1.0× 234 0.2× 254 0.4× 231 0.4× 48 2.9k
Reiko Sasada Japan 26 421 0.3× 1.6k 1.2× 137 0.1× 428 0.6× 442 0.9× 50 2.9k
K Yamamura Japan 22 530 0.4× 1.1k 0.8× 111 0.1× 375 0.5× 193 0.4× 39 2.5k
Gabriele Proetzel United States 14 710 0.5× 2.2k 1.5× 160 0.1× 173 0.2× 319 0.6× 22 3.7k
Hiroh Saji Japan 28 437 0.3× 1.5k 1.1× 257 0.2× 185 0.3× 468 0.9× 91 3.7k
Monika Dohse United States 7 131 0.1× 1.3k 0.9× 218 0.2× 292 0.4× 910 1.8× 8 2.6k
Ken-ichiro Kosai Japan 23 466 0.3× 1.1k 0.8× 86 0.1× 173 0.2× 415 0.8× 47 2.2k

Countries citing papers authored by Katherine P. Ponder

Since Specialization
Citations

This map shows the geographic impact of Katherine P. Ponder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine P. Ponder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine P. Ponder more than expected).

Fields of papers citing papers by Katherine P. Ponder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine P. Ponder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine P. Ponder. The network helps show where Katherine P. Ponder may publish in the future.

Co-authorship network of co-authors of Katherine P. Ponder

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine P. Ponder. A scholar is included among the top collaborators of Katherine P. Ponder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine P. Ponder. Katherine P. Ponder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, Lachlan J., Guilherme Baldo, Susan Wu, et al.. (2012). Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII. Molecular Genetics and Metabolism. 107(1-2). 153–160. 24 indexed citations
2.
Ponder, Katherine P., Thomas O’Malley, Ping Wang, et al.. (2012). Neonatal Gene Therapy With a Gamma Retroviral Vector in Mucopolysaccharidosis VI Cats. Molecular Therapy. 20(5). 898–907. 20 indexed citations
3.
Baldo, Guilherme, Susan Wu, Russell H. Knutsen, et al.. (2011). Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Molecular Genetics and Metabolism. 104(4). 608–619. 42 indexed citations
4.
Dickson, Patricia, N. Matthew Ellinwood, Karen L. Kline, et al.. (2010). 36. Intrathecal enzyme replacement therapy treats meningeal storage and spinal cord compression in MPS I dogs. Molecular Genetics and Metabolism. 99(2). S15–S15. 2 indexed citations
5.
Herati, Ramin S., Van W. Knox, Patricia O’Donnell, et al.. (2008). Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Molecular Genetics and Metabolism. 95(3). 142–151. 40 indexed citations
6.
Ma, Xiucui, Yuli Liu, Anne K. Hennig, et al.. (2007). Improvements in Mucopolysaccharidosis I Mice After Adult Retroviral Vector–mediated Gene Therapy with Immunomodulation. Molecular Therapy. 15(5). 889–902. 50 indexed citations
7.
Traas, Anne M., Ping Wang, Xiucui Ma, et al.. (2007). Correction of Clinical Manifestations of Canine Mucopolysaccharidosis I with Neonatal Retroviral Vector Gene Therapy. Molecular Therapy. 15(8). 1423–1431. 80 indexed citations
8.
Lu, Xu, et al.. (2007). High expression reduces an antibody response after neonatal gene therapy with B domain‐deleted human factor VIII in mice. Journal of Thrombosis and Haemostasis. 5(9). 1805–1812. 25 indexed citations
9.
Spitzer, Dirk, Xiaobo Wu, Xiucui Ma, et al.. (2006). Cutting Edge: Treatment of Complement Regulatory Protein Deficiency by Retroviral In Vivo Gene Therapy. The Journal of Immunology. 177(8). 4953–4956. 10 indexed citations
10.
11.
Ponder, Katherine P.. (2006). Gene therapy goes to the dogs. Blood. 107(8). 3018–3019. 1 indexed citations
12.
Wang, Bin, Cuihua Gao, & Katherine P. Ponder. (2005). C/EBPβ contributes to hepatocyte growth factor-induced replication of rodent hepatocytes. Journal of Hepatology. 43(2). 294–302. 11 indexed citations
13.
Xu, Lingfei, Mark S. Sands, Bin Wang, et al.. (2004). In vivo transduction of hematopoietic stem cells after neonatal intravenous injection of an amphotropic retroviral vector in mice. Molecular Therapy. 10(1). 37–44. 18 indexed citations
14.
15.
Liu, Yuli, Lingfei Xu, Anne K. Hennig, et al.. (2004). Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Molecular Therapy. 11(1). 35–47. 73 indexed citations
16.
Cai, Shi-Rong, et al.. (2001). Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4α in rat liver. Hepatology. 34(5). 979–989. 50 indexed citations
17.
Cai, Shi-Rong, et al.. (2000). Lovastatin decreases mortality and improves liver functions in fulminant hepatic failure from 90% partial hepatectomy in rats. Journal of Hepatology. 32(1). 67–77. 19 indexed citations
18.
Wu, Xiaoyun, et al.. (1996). Retroviral Vector Sequences May Interact with Some Internal Promoters and Influence Expression. Human Gene Therapy. 7(2). 159–171. 20 indexed citations
19.
Pearline, Rachel V., Yiing Lin, Kezhen Shen, et al.. (1996). Alterations in Enzymatic Functions in Hepatocytes and Hepatocellular Carcinomas From Ras –Transduced Livers Resemble the Effects of Insulin. Hepatology. 24(4). 838–848. 8 indexed citations
20.
Okuyama, Torayuki, Reid Huber, William M. Bowling, et al.. (1996). Liver-Directed Gene Therapy: A Retroviral Vector with a Complete LTR and the ApoE Enhancer- α 1 -Antitrypsin Promoter Dramatically Increases Expression of Human α 1 -Antitrypsin In Vivo. Human Gene Therapy. 7(5). 637–645. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Akihiko Ito Breakdown of academic impact, for papers by Andrés F. Muro Breakdown of academic impact, for papers by Jean Michel Heard Breakdown of academic impact, for papers by Elizabeth L. Buza Breakdown of academic impact, for papers by Reiko Sasada Breakdown of academic impact, for papers by K Yamamura Breakdown of academic impact, for papers by Gabriele Proetzel Breakdown of academic impact, for papers by Hiroh Saji Breakdown of academic impact, for papers by Monika Dohse Breakdown of academic impact, for papers by Ken-ichiro Kosai
Rankless by CCL
2026